WHOLE-BODY F-18 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY IN PREOPERATIVE EVALUATION OF LUNG-CANCER

Citation
P. Lewis et al., WHOLE-BODY F-18 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY IN PREOPERATIVE EVALUATION OF LUNG-CANCER, Lancet, 344(8932), 1994, pp. 1265-1266
Citations number
9
Categorie Soggetti
Medicine, General & Internal
Journal title
LancetACNP
ISSN journal
01406736
Volume
344
Issue
8932
Year of publication
1994
Pages
1265 - 1266
Database
ISI
SICI code
0140-6736(1994)344:8932<1265:WFFPET>2.0.ZU;2-9
Abstract
Despite use of computed tomography, some lung cancer patients are foun d to have unresectable disease at surgery, or they present early with metastases. We studied whether whole-body -positron emission tomograph y (PET) with F-18-fluorodeoxyglucose ((18)FDG) would improve the preop erative detection of metastases. We retrospectively analysed 34 patien ts with ''operable'' non-small-cell lung cancer who underwent (18)FDG PET after routine assessment. Management changes produced by the PET s can and confirmatory tests were reviewed. PET unsuspected malignant le sions in 10 (29%) Management changes occurred in 14 (41%), including 6 (18%) patients who were changed to non-surgical therapy. These data s uggest that whole-body (18)FDG PET improves preoperative assessment of lung cancer patients.